Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

WBOY

Published November 13, 2026 · Updated November 15, 2026

Trump administration will fund new research on controversial psychedelic drug ibogaine

Read the full story at WBOY

Ibogaine is currently illegal, in the same ultra-restrictive class as LSD, ecstasy and most other psychedelic drugs . Veterans organizations and.

Surfaced by 4 Google Alerts

  • Psychedelics south america
  • Ibogaine
  • Psychedelic crime
  • Psychedelic press release